First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial - Özgüroğlu, Mustafa; Kilickap, Saadettin; Sezer, Ahmet; Gümüş, Mahmut; Bondarenko, Igor; Gogishvili, Miranda; Nechaeva, Marina; Schenker, Michael; Cicin, Irfan; Ho, Gwo Fuang; Kulyaba, Yaroslav; Zyuhal, Kasimova; et al. (The lancet oncology, 2023)
Keywords: Adverse events; Cancer therapies; Chemotherapy; Embolism; Empowerment; FDA approval; Heart diseases; Hematology, Oncology, and Palliative Medicine; Histology; Immunotherapy; Lung cancer; Lung diseases; Medical prognosis; Metastasis; Monoclonal antibodies; Mutation; Myocardial infarction; Myocarditis; Nephritis; Neutropenia; Non-small cell lung carcinoma; Patients; PD-L1 protein; Pneumonia; Response rates; Septic shock; Solid tumors; Targeted cancer therapy; Tumors